Bill No. HB 1297 (2020)

Amendment No. 1

	COMMITTEE/SUBCOMMITTEE ACTION
	ADOPTED (Y/N)
	ADOPTED AS AMENDED (Y/N)
	ADOPTED W/O OBJECTION (Y/N)
	FAILED TO ADOPT (Y/N)
	WITHDRAWN (Y/N)
	OTHER
1	Committee/Subcommittee hearing bill: Workforce Development &
2	Tourism Subcommittee
3	Representative Robinson offered the following:
4	
5	Amendment (with title amendment)
6	Remove everything after the enacting clause and insert:
7	Section 1. Present subsections (13) through (17) of section
8	112.0455, Florida Statutes, are redesignated as subsections (14)
9	through (18), respectively, a new subsection (13) is added to
10	that section, and paragraph (b) of subsection (6) and paragraph
11	(a) of present subsection (15) are amended, to read:
12	112.0455 Drug-Free Workplace Act
13	(6) NOTICE TO EMPLOYEES.—

264657 - h1297-strike.docx

employer which contains:

14

15

16

Published On: 2/3/2020 3:41:57 PM

employment shall be given a written policy statement from the

(b) Prior to testing, all employees and job applicants for

- 1. A general statement of the employer's policy on employee drug use, which shall identify:
- a. The types of testing an employee or job applicant may be required to submit to, including reasonable suspicion or other basis; and
- b. The actions the employer may take against an employee or job applicant on the basis of a positive confirmed drug test result.
- 2. A statement advising the employee or job applicant of the existence of this section.
 - 3. A general statement concerning confidentiality.
- 4. Procedures for employees and job applicants to confidentially report the use of prescription or nonprescription medications both before and after being tested. Additionally, employees and job applicants shall receive notice of the most common medications by brand name or common name, as applicable, as well as by chemical name, which may alter or affect a drug test. A list of such medications shall be developed by the Agency for Health Care Administration.
 - 5. The consequences of refusing to submit to a drug test.
- 6. Names, addresses, and telephone numbers of employee assistance programs and local alcohol and drug rehabilitation programs.
- 7. A statement that an employee or job applicant who receives a positive confirmed drug test result may contest or

264657 - h1297-strike.docx

explain the result to the employer within 5 working days after written notification of the positive test result. If an employee or job applicant's explanation or challenge is unsatisfactory to the employer, the person may contest the drug test result as provided by subsections (15) $\frac{14}{14}$ and (16) $\frac{15}{15}$.

- 8. A statement informing the employee or job applicant of his or her responsibility to notify the laboratory of any administrative or civil actions brought pursuant to this section.
- 9. A list of all drugs for which the employer will test, described by brand names or common names, as applicable, as well as by chemical names.
- 10. A statement regarding any applicable collective bargaining agreement or contract and the right to appeal to the Public Employees Relations Commission.
- 11. A statement notifying employees and job applicants of their right to consult the testing laboratory for technical information regarding prescription and nonprescription medication.
- (13) DRUG-TESTING STANDARDS; SAMPLE VALIDITY

 PRESCREENING.—Before a drug-testing facility licensed under part

 II of chapter 408 may perform any drug-screening test on a urine

 specimen collected in this state, prescreening tests must be

 performed to determine the validity of the specimen. The

 prescreening tests must be capable of detecting, or detecting

264657 - h1297-strike.docx

- and defeating, novel or emerging urine drug-testing subversion technologies as described in this subsection.
- (a) The drug-testing facility shall use urine sample validity screening tests that meet all of the following criteria:
- 1. A urine sample validity screening test for creatinine must use a 20 mg/dL cutoff concentration and must have minimal interferences from bilirubin and blood in the urine. The urine sample validity screening test must be able to discriminate between a creatinine level from an unadulterated urine sample and a creatinine level arising from overhydration or creatine or protein loading.
- 2. A urine sample validity screening test for oxidants must be able to detect the presence or effects of oxidant adulterants up to 6 days after sample collection, under the sample storage conditions outlined in the laboratory standards guideline adopted by rule by the Agency for Health Care Administration, and after any sample transport that is routinely involved.
- 3. Urine sample validity screening tests must be able to detect synthetic or freeze-dried urine substituted for the donor's urine for drug testing.
- 4. Urine sample validity screening tests must be validated for the detection of all of the additional adulterant classes represented by glutaraldehyde, salt, heavy metals, cationic

264657 - h1297-strike.docx

detergents, protease, strong alkaline buffers, and strong acidi-
buffers. The detection limits of these classes must be at a
sufficient level to detect a nonphysiologic sample or
interference with enzyme immunoassay drug screening tests.

- (b) The drug-testing facility may use only urine sample validity screening tests that have undergone validation studies conducted by the manufacturer to document the product's conformance to the requirements of this subsection.
- (c) A drug-testing facility may rely on urine sample validity screening tests to determine if confirmation testing is required for any urine sample that has been deemed invalid for drug screening.
- (d) Urine specimens collected in this state may not be sent for drug screening tests to a drug-testing facility located outside of this state unless such drug-testing facility complies with all requirements of this subsection.
- (e) The Agency for Health Care Administration shall adopt rules necessary for the implementation and enforcement of this subsection.
 - (16) (15) NONDISCIPLINE REMEDIES.-
- (a) Any person alleging a violation of the provisions of this section, that is not remediable by the commission or an arbitrator pursuant to subsection (15) (14), must institute a civil action for injunctive relief or damages, or both, in a court of competent jurisdiction within 180 days of the alleged

264657 - h1297-strike.docx

117	violation,	or be	barred	from	obtaining	the	following	relief.
118	Relief is	limited	d to:					

- 1. An order restraining the continued violation of this section.
- 2. An award of the costs of litigation, expert witness fees, reasonable attorney attorney's fees, and noneconomic damages provided that damages shall be limited to the recovery of damages directly resulting from injury or loss caused by each violation of this section.
- Section 2. Present subsections (9) through (15) of section 440.102, Florida Statutes, are redesignated as subsections (10) through (16), respectively, a new subsection (9) is added to that section, and paragraphs (c), (e), and (q) of subsection (1), paragraph (a) of subsection (3), paragraphs (b) through (h), (j), (k), and (l) of subsection (5), subsection (6), paragraph (a) of subsection (7), and paragraphs (b) and (c) of present subsection (9) of that section are amended, to read:
- 440.102 Drug-free workplace program requirements.—The following provisions apply to a drug-free workplace program implemented pursuant to law or to rules adopted by the Agency for Health Care Administration:
- (1) DEFINITIONS.—Except where the context otherwise requires, as used in this act:
- (c) "Drug" means <u>any form of</u> alcohol, <u>as defined in s.</u>

 322.01(2), including a distilled spirit, wine, a malt beverage,

264657 - h1297-strike.docx

142	or an intoxicating preparation; any controlled substance
143	identified under Schedule I, Schedule II, Schedule III, Schedule
144	IV, or Schedule V of s. 893.03; any controlled substance
145	identified under Schedule I, Schedule II, Schedule III, Schedule
146	IV, or Schedule V of the Controlled Substances Act, 21 U.S.C. s.
147	812(c) liquor; an amphetamine; a cannabinoid; cocaine;
148	phencyclidine (PCP); a hallucinogen; methaqualone; an opiate; a
149	barbiturate; a benzodiazepine; a synthetic narcotic; a designer
150	drug; or a metabolite of any of the substances listed in this
151	paragraph. An employer may test an individual for any or all of
152	such drugs.

- (e) "Drug test" or "test" means any chemical, biological, or physical instrumental analysis administered, by a laboratory certified by the United States Department of Health and Human Services or licensed by the Agency for Health Care Administration, for the purpose of determining the presence or absence of a drug or its metabolites. In the case of testing for the presence of alcohol, the test must be conducted in accordance with the United States Department of Transportation alcohol testing procedures authorized under 49 C.F.R. part 40, subparts J through M.
- (q) "Specimen" means tissue, hair, or a product of the human body capable of revealing the presence of drugs or their metabolites, as approved by the United States Food and Drug Administration, or the Agency for Health Care Administration,

264657 - h1297-strike.docx

the	United	States	Department	of	Health	and	Human	Services,	or
the	United	States	Department	of	Transpo	ortat	tion.		

- (3) NOTICE TO EMPLOYEES AND JOB APPLICANTS.-
- (a) One time only, <u>before</u> prior to testing, an employer shall give all employees and job applicants for employment a written policy statement that which contains:
- 1. A general statement of the employer's policy on employee drug use, which must identify:
- a. The types of drug testing an employee or job applicant may be required to submit to, including reasonable-suspicion drug testing or drug testing conducted on any other basis.
- b. The actions the employer may take against an employee or job applicant on the basis of a positive confirmed drug test result.
- 2. A statement advising the employee or job applicant of the existence of this section.
 - 3. A general statement concerning confidentiality.
- 4. Procedures for employees and job applicants to confidentially report to a medical review officer the use of prescription or nonprescription medications to a medical review officer both before and after being tested.
- 5. A list of the most common medications, by brand name or common name, as applicable, as well as by chemical name, which may alter or affect a drug test. A list of such medications as

264657 - h1297-strike.docx

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211212

developed by the Agency for Health Care Administration shall be available to employers through the department.

- 6. The consequences of refusing to submit to a drug test.
- 7. A representative sampling of names, addresses, and telephone numbers of employee assistance programs and local drug rehabilitation programs.
- 8. A statement that an employee or job applicant who receives a positive confirmed test result may contest or explain the result to the medical review officer within 5 working days after receiving written notification of the test result; that if an employee's or job applicant's explanation or challenge is unsatisfactory to the medical review officer, the medical review officer shall report a positive test result back to the employer; and that a person may contest the drug test result pursuant to law or to rules adopted by the Agency for Health Care Administration.
- 9. A statement informing the employee or job applicant of his or her responsibility to notify the laboratory of any administrative or civil action brought pursuant to this section.
- 10. A list of all drugs for which the employer will test, described by brand name or common name, as applicable, as well as by chemical name.
- 213 11. A statement regarding any applicable collective 214 bargaining agreement or contract and the right to appeal to the 215 Public Employees Relations Commission or applicable court.

264657 - h1297-strike.docx

12. A stat	tement notifying e	employees and job	applicants of
their right to o	consult with a med	dical review offi	cer for
technical inform	mation regarding p	rescription or n	onprescription
medication.			

- (5) PROCEDURES AND EMPLOYEE PROTECTION.—All specimen collection and testing for drugs under this section shall be performed in accordance with the following procedures:
- (b) Specimen collection must be documented, and the documentation procedures shall include the \div
- 1. labeling of specimen containers so as to reasonably preclude the likelihood of erroneous identification of test results. For saliva or breath alcohol testing, a specimen container is not required if the specimen is not being transported to a laboratory for analysis
- 2. A form for the employee or job applicant to provide any information he or she considers relevant to the test, including identification of currently or recently used prescription or nonprescription medication or other relevant medical information. The form must provide notice of the most common medications by brand name or common name, as applicable, as well as by chemical name, which may alter or affect a drug test. The providing of information shall not preclude the administration of the drug test, but shall be taken into account in interpreting any positive confirmed test result.

264657 - h1297-strike.docx

- (c) Specimen collection, storage, and transportation to \underline{a} laboratory the testing site shall be performed in a manner that reasonably precludes contamination or adulteration of specimens.
- (d) Each confirmation test conducted under this section, not including the taking or collecting of a specimen to be tested, shall be conducted by a licensed or certified laboratory as described in subsection (10) (9).
- (e) A specimen for a drug test may be taken or collected by any person who meets the qualification standards for urine or oral fluid specimen collection as specified by the United States

 Department of Health and Human Services or the United States

 Department of Transportation. For alcohol testing, a person must meet the United States Department of Transportation standards for a screening test technician or a breath alcohol technician.

 A hair specimen may be collected and packaged by a person who has been trained and certified by a drug-testing laboratory. A person who directly supervises an employee subject to testing may not serve as the specimen collector for that employee unless there is no other qualified specimen collector available of the following persons:
- 1. A physician, a physician assistant, a registered professional nurse, a licensed practical nurse, or a nurse practitioner or a certified paramedic who is present at the scene of an accident for the purpose of rendering emergency medical service or treatment.

264657 - h1297-strike.docx

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

- 2. A qualified person employed by a licensed or certified laboratory as described in subsection (9).
- (f) A person who collects or takes a specimen for a drug test shall collect an amount sufficient for two <u>independent</u> drug tests, one to screen the specimen and one for confirmation of the screening test results, at a laboratory as determined by the Agency for Health Care Administration.
- Every specimen that produces a positive, confirmed test result shall be preserved by the licensed or certified laboratory that conducted the confirmation test for a period of at least 1 year after the confirmation test was conducted $\frac{210}{210}$ days after the result of the test was mailed or otherwise delivered to the medical review officer. However, if an employee or job applicant undertakes an administrative or legal challenge to the test result, the employee or job applicant shall notify the laboratory and the sample shall be retained by the laboratory until the case or administrative appeal is settled. During the 60-day 180-day period after written notification of a positive test result, the employee or job applicant who has provided the specimen shall be permitted by the employer to have a portion of the specimen retested, at the employee's or job applicant's expense, at another laboratory, licensed and approved by the Agency for Health Care Administration, chosen by the employee or job applicant. The second laboratory must test the specimen at the limit of detection for the drug or analyte

264657 - h1297-strike.docx

confirmed by the original at equal or greater sensitivity for the drug in question as the first laboratory. If the drug or analyte is detected by the second laboratory, the result must be reported as reconfirmed positive. The first laboratory that performed the test for the employer is responsible for the transfer of the portion of the specimen to be retested, and for the integrity of the chain of custody during such transfer.

- (h) Within 5 working days after receipt of a positive verified confirmed test result from the medical review officer, an employer shall inform an employee or job applicant in writing of such positive test result, the consequences of such result results, and the options available to the employee or job applicant. The employer shall provide to the employee or job applicant, upon request, a copy of the test results.
- challenge of the positive test result is unsatisfactory to the employer, a written explanation as to why the employee's or job applicant's explanation is unsatisfactory, along with the report of positive result, shall be provided by the employer to the employee or job applicant; and All such documentation of a positive test shall be kept confidential by the employer pursuant to subsection (8) and shall be retained by the employer for at least 1 year.
- (k) An employer may not discharge, discipline, refuse to hire, discriminate against, or request or require rehabilitation

264657 - h1297-strike.docx

of an employee or job applicant on the sole basis of a positive
test result that has not been $\underline{\text{reviewed and}}$ verified by $\frac{\text{a}}{\text{c}}$
confirmation test and by a medical review officer, except when a
confirmed positive breath alcohol test was conducted in
accordance with United States Department of Transportation
alcohol testing procedures.

- (1) An employer that performs drug testing or specimen collection shall use chain-of-custody procedures established by the Agency for Health Care Administration, the United States

 Department of Health and Human Services, or the United States

 Department of Transportation to ensure proper recordkeeping, handling, labeling, and identification of all specimens tested.
 - (6) CONFIRMATION TESTING.-
- (a) If an initial drug test is negative, the employer may in its sole discretion seek a confirmation test.
- (b) Only licensed or certified laboratories as described in subsection (9) may conduct confirmation drug tests.
- (c) All <u>laboratory</u> positive initial tests <u>on a urine</u>, <u>oral</u> <u>fluid</u>, <u>blood</u>, <u>or hair specimen</u> shall be confirmed using gas chromatography/mass spectrometry (GC/MS) or an equivalent or more accurate scientifically accepted method approved by the <u>United States Department of Health and Human Services or the United States Department of Transportation Agency for Health <u>Care Administration or the United States Food and Drug</u></u>

264657 - h1297-strike.docx

Administration as such technology becomes available in a costeffective form.

- (b) (d) If a an initial drug test of an employee or job applicant is confirmed by the laboratory as positive, the employer's medical review officer shall provide technical assistance to the employer and to the employee or job applicant for the purpose of interpreting the test result to determine whether the result could have been caused by prescription or nonprescription medication taken by the employee or job applicant.
- (c) For a breath alcohol test, an initial positive result must be confirmed by a second breath specimen taken and tested using an evidential breath testing device listed on the conforming products list issued by the National Highway Traffic Safety Administration and conducted in accordance with United States Department of Transportation alcohol testing procedures authorized under 49 C.F.R. part 40, subparts J through M.
 - (7) EMPLOYER PROTECTION. -
- (a) An employee or job applicant whose drug test result is confirmed <u>or verified</u> as positive in accordance with this section shall not, by virtue of the result alone, be deemed to have a "handicap" or "disability" as defined under federal, state, or local handicap and disability discrimination laws.
- (9) DRUG-TESTING STANDARDS; SAMPLE VALIDITY PRESCREENING.— Before a drug-testing facility licensed under part II of chapter

264657 - h1297-strike.docx

408 may perform any drug screening test on a urine specimen
collected in this state, prescreening tests must be performed to
determine the validity of the specimen. The prescreening tests
must be capable of detecting, or detecting and defeating, novel
or emerging urine drug-testing subversion technologies as
described in this subsection.

- (a) The drug-testing facility shall use urine sample validity screening tests that meet all of the following criteria:
- 1. A urine sample validity screening test for creatinine must use a 20 mg/dL cutoff concentration and must have minimal interferences from bilirubin and blood in the urine. The urine sample validity screening test must be able to discriminate between a creatinine level from an unadulterated urine sample and a creatinine level arising from overhydration or creatine or protein loading.
- 2. A urine sample validity screening test for oxidants must be able to detect the presence or effects of oxidant adulterants up to 6 days after sample collection, under the sample storage conditions outlined in the laboratory standards guideline adopted by rule by the Agency for Health Care Administration, and after any sample transport that is routinely involved.

264657 - h1297 - strike.docx

	3.	Urine	samp	le	valid	lity	scr	eenir	ng	tests	must	be	able	to
detec	ct :	synthet	ic or	fr	eeze-	drie	d u	rine	su	ıbstit	uted	for	the	
donor	c's	urine :	for di	rug	test	ing.								

- 4. Urine sample validity screening tests must be validated for the detection of all of the additional adulterant classes represented by glutaraldehyde, salt, heavy metals, cationic detergents, protease, strong alkaline buffers, and strong acidic buffers. The detection limits of these classes must be at a sufficient level to detect a nonphysiologic sample or interference with enzyme immunoassay drug-screening tests.
- (b) The drug-testing facility may use only urine sample validity screening tests that have undergone validation studies conducted by the manufacturer to document the product's conformance to the requirements of this subsection.
- (c) A drug-testing facility may rely on urine sample validity screening tests to determine if confirmation testing is required for any urine sample that has been deemed invalid for drug screening.
- (d) Urine specimens collected in this state may not be sent for drug-screening tests to a drug-testing facility located outside of this state unless such drug-testing facility complies with all requirements of this subsection.
- (e) The Agency for Health Care Administration shall adopt rules necessary for the implementation and enforcement of this subsection.

264657 - h1297 - strike.docx

412	(1	() + (9)	DRUG-	-TESTING	STANDARDS	FOR	LABORATORIES.	_
$\neg \perp \bot$	(_	\cup $)$ $($.	<i>)</i>	DI(OO	THUTTING	O I I I I I D I I I I D D	TOIL	TITOTUTTOTTED.	

- (b) A laboratory may analyze initial or confirmation test specimens only if:
- 1. The laboratory obtains a license under part II of chapter 408 and $\underline{s.\ 112.0455(18)}\ \underline{s.\ 112.0455(17)}$. Each applicant for licensure and each licensee must comply with all requirements of this section, part II of chapter 408, and applicable rules.
- 2. The laboratory has written procedures to ensure the chain of custody.
- 3. The laboratory follows proper quality control procedures, including, but not limited to:
- a. The use of internal quality controls, including the use of samples of known concentrations which are used to check the performance and calibration of testing equipment, and periodic use of blind samples for overall accuracy.
- b. An internal review and certification process for drug test results, conducted by a person qualified to perform that function in the testing laboratory.
- c. Security measures implemented by the testing laboratory to preclude adulteration of specimens and drug test results.
- d. Other necessary and proper actions taken to ensure reliable and accurate drug test results.
- (c) A laboratory shall disclose to the medical review officer a written positive confirmed test result report within 7

264657 - h1297-strike.docx

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

437	working	days	after r	eceipt	of	the	sample.	All	laboratory	reports
438	of a dr	ug tes	t resul	t must,	at	aı	minimum,	stat	ce:	

- 1. The name and address of the laboratory that performed the test and the positive identification of the person tested.
- 2. Positive results on confirmation tests only, or negative results, as applicable.
- 3. A list of the drugs for which the drug analyses were conducted.
- 4. The type of tests conducted for both initial tests and confirmation tests and the minimum cutoff levels of the tests.
- 5. Any correlation between medication reported by the employee or job applicant pursuant to subparagraph (5) (b) 2. and a positive confirmed drug test result.

A report must not disclose the presence or absence of any drug other than a specific drug and its metabolites listed pursuant to this section.

Section 3. Paragraph (b) of subsection (11) of section 443.101, Florida Statutes, is amended to read:

- 443.101 Disqualification for benefits.—An individual shall be disqualified for benefits:
- (11) If an individual is discharged from employment for drug use as evidenced by a positive, confirmed drug test as provided in paragraph (1)(d), or is rejected for offered employment because of a positive, confirmed drug test as

264657 - h1297-strike.docx

Amendment No. 1

provided in paragraph (2)(c), test results and chain of custody						
documentation provided to the employer by a licensed and						
approved drug-testing laboratory is self-authenticating and						
admissible in reemployment assistance hearings, and such						
evidence creates a rebuttable presumption that the individual						
used, or was using, controlled substances, subject to the						
following conditions:						

(b) Only laboratories licensed and approved as provided in $\underline{s.\ 440.102(10)}$ $\underline{s.\ 440.102(9)_{7}}$ or as provided by equivalent or more stringent licensing requirements established by federal law or regulation may perform the drug tests.

Section 4. This act shall take effect July 1, 2020.

474

473

462

463

464 465

466

467

468

469

470

471472

475476

477

478

479

481

483

484

485 486

TITLE AMENDMENT

Remove everything before the enacting clause and insert:

A bill to be entitled

An act relating to drug-free workplaces; amending s.

480 112.0455, F.S.; requiring licensed drug-testing

facilities to perform prescreening tests on urine

specimens to determine the specimens' validity;

specifying requirements for such tests; authorizing

such facilities to rely on such tests to determine if

confirmation testing is required; providing that urine

specimens may not be sent to an out-of-state facility

264657 - h1297-strike.docx

Amendment No. 1

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

unless the facility complies with certain requirements; authorizing the Agency for Health Care Administration to adopt rules; conforming crossreferences; amending s. 440.102, F.S.; revising definitions; revising information required in a written policy statement provided to employees and job applicants before drug testing; revising procedures for specimen collection, testing, and preservation; revising qualifications for persons who may take or collect specimens for a drug test; revising requirements and procedures for retesting specimens; deleting and revising confidentiality requirements for employers relating to certain information; revising circumstances under which an employer may take certain actions as to an employee or a job applicant on the sole basis of certain positive test results; revising standards for chain-of-custody procedures; revising requirements and authorized actions relating to confirmation testing; requiring licensed drug-testing facilities to perform prescreening tests on urine specimens to determine the specimens' validity; specifying requirements for such tests; authorizing such facilities to rely on such tests to determine if confirmation testing is required; providing that urine specimens may not be sent to an out-of-state facility

264657 - h1297-strike.docx

COMMITTEE/SUBCOMMITTEE AMENDMENT Bill No. HB 1297 (2020)

Amendment No. 1

512	unless the facility complies with certain
513	requirements; authorizing the agency to adopt rules;
514	conforming provisions to changes made by the act;
515	amending s. 443.101, F.S.; conforming a cross-
516	reference; providing an effective date.
517	
518	WHEREAS, the State of Florida has a profound interest in
519	the health and welfare of its citizens, and

WHEREAS, new and emerging drug-testing subversion technologies represent a significant threat to the ability to properly identify those suffering from addiction and drug abuse, and

WHEREAS, the Legislature, therefore, seeks to require urine sample validity testing, such that those persons being tested can be properly and promptly identified for referral to drug treatment programs and other health care services, NOW, THEREFORE,

529

520

521522

523

524

525

526

527

528

264657 - h1297-strike.docx